New capital enables Avenacy to continue rapid growth and expand access to injectable medications
Avenacy, a specialty pharmaceutical company committed to supplying critical injectable medications to the U.S. market, announced that it has entered into an Asset Based Lending (ABL) agreement with Texas Capital Bank. The agreement provides Avenacy with the financial flexibility to accelerate its growth and support the continued expansion of its product portfolio to better serve healthcare providers, hospitals, and patients nationwide.
Financial Technology Insights: EBANX Powers APLAZO BNPL Global e‑Commerce in Mexico
“The launch of twenty-three products in under two years reflects the strength of our partnership-driven model and commercial execution,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “This financing enables us to build on the strong momentum we’ve achieved since inception and continue expanding access to high-quality injectable medications across the U.S. healthcare system.”
Financial Technology Insights: Camden National Bank Taps Spiral for Personalized Savings Tools
The capital from this agreement will enable Avenacy to advance near-term product launches and pursue key initiatives that reinforce its position as a reliable supplier of essential injectable medications. It will also fund strategic investments in the Company’s long-term growth portfolio, with a focus on high-return and market-formation products. With a portfolio of thirty products expected by year-end 2025, this financing marks a pivotal step in expanding Avenacy’s market presence and supporting sustained growth.
FTI Capital Advisors served as financial advisors to Avenacy for this capital raise.
Financial Technology Insights: Financial Center First CU Selects Scienaptic AI to Transform Lending
To share your insights with the FinTech Newsroom, please write to us at sudipto@intentamplify.com
Source: businesswire
